IL33 and neoplasm: However, TA99 CAR-T cells expressing both Super2 and IL-33 (Super2 + IL-33) was shown to have enduring effectiveness in delaying medium-sized tumor growth (∼7.5 mm × 6 mm) when administered on day 11 after inoculation.